Figure 1
![Figure 1. Schema of intrathecal (IT) chemotherapy for the hyper-CVAD regimen with standard IT compared with IT liposomal cytarabine. Standard IT therapy consisted of methotrexate (MTX) 12 mg on day 2 and cytarabine 100 mg on day 7 of each course of therapy until completion based on risk group (6 for low-risk [LR], 8 for indeterminate- or high-risk [HR], 16 for Burkitt-type). Liposomal cytarabine 50 mg was given on days 1 and 15 of each course of hyper-CVAD and on day 10 of each course of high-dose MTX-cytarabine until completion (3 for low-risk, 6 for indeterminate- or high-risk, 10 for Burkitt-type). Arrows indicate IT treatments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/109/8/10.1182_blood-2006-08-043646/4/zh80080711310001.jpeg?Expires=1724236065&Signature=lAEK~OFng8FXYXRBRCUzfkNH7uJeou2FAUGFQwDly0tQz0NSAKxS49pQas1HnLxUpTaTcIY2tKrbw2VQSSpHSPqQX8we0ta0kEalPW-wJIIclNPnuKS3ojdIpXBmww7b06Rizww84mILH20JNr9N0jRqrFWMpzw2nG9QRojAVpy9AFGc13Gyh9pvCBabKxiSm2CKR7a4hxGdbaxaQW8l9HNC292kDYuGCDxaBhDfI80NNeXjWELQFOg~VI7x5~gC0bB-0lXzLs~vq5aI-zxTmT89ub~P1Kz2QmFyqLvipt9ivkRLqDFKVO49WVTyyiOiQj0AdOWveRa~5ahjANXSOw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Schema of intrathecal (IT) chemotherapy for the hyper-CVAD regimen with standard IT compared with IT liposomal cytarabine. Standard IT therapy consisted of methotrexate (MTX) 12 mg on day 2 and cytarabine 100 mg on day 7 of each course of therapy until completion based on risk group (6 for low-risk [LR], 8 for indeterminate- or high-risk [HR], 16 for Burkitt-type). Liposomal cytarabine 50 mg was given on days 1 and 15 of each course of hyper-CVAD and on day 10 of each course of high-dose MTX-cytarabine until completion (3 for low-risk, 6 for indeterminate- or high-risk, 10 for Burkitt-type). Arrows indicate IT treatments.
